Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Cardiometabolic Risk

CoverageCardiometabolic Risk

Do therapies that raise HDL reduce cardiovascular events?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·11 studies analyzed·2 core studies·Applies to: men with preexisting or high cardiovascular risk

Bottom line

Trials of niacin and CETP inhibitors raised HDL without consistent reduction in cardiovascular events when added to statins, challenging the hypothesis that raising HDL alone is protective.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. HDL as a treatment target remains disputed after neutral outcome trials.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

HDL raising cardiovascular benefit▼

Trials of niacin and CETP inhibitors raised HDL without consistent reduction in cardiovascular events when added to statins, challenging the hypothesis that raising HDL alone is protective.

Niacin HDL outcomes▼

Trials of niacin and CETP inhibitors raised HDL without consistent reduction in cardiovascular events when added to statins, challenging the hypothesis that raising HDL alone is protective.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 11 relevant studies.

Overall finding

6 studies address ldl-c, with weighted findings showing a negative association. 6 studies address major adverse cardiovascular events, with weighted findings showing a positive association. 2 studies address mortality, with weighted findings showing a negative association. 2 studies address apolipoprotein b, with weighted findings showing unclear findings. Do not add niacin or CETP inhibitors solely to raise HDL when LDL is already treated. Focus on LDL/apoB reduction and global risk; raising HDL pharmacologically has not consistently reduced events in outcome trials.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Negative link

LDL-C

high · 6 studies

6 studies address ldl-c, with weighted findings showing a negative association. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 31447131PMID 22607822PMID 18997196PMID 34773460PMID 38700053PMID 42526419
Positive link

Major adverse cardiovascular events

moderate · 6 studies

6 studies address major adverse cardiovascular events, with weighted findings showing a positive association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 34637926PMID 18997196PMID 41403046PMID 42291041PMID 22910756PMID 42526419
Negative link

Mortality

moderate · 2 studies

2 studies address mortality, with weighted findings showing a negative association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 22607822PMID 42291041
Unclear

Apolipoprotein B

limited · 2 studies

2 studies address apolipoprotein b, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 34773460PMID 38700053
Unclear

Blood pressure

limited · 1 study

1 study addresses blood pressure, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 41101894

Magnitude / clinical importance

Validated effect estimates in the analyzed set include RR 0; hazard ratio 2.21; HR 1.96; hazard ratio 1.06. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Findings are mostly consistent with minor variation after weighting by design, quality, and directness.

Supports main conclusion: 3 · Neutral / mixed: 6 · Credible conflicting: 2

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascul…
  • Lipid management typically focuses on levels of low-density lipoprotein cholesterol (LDL-C) and, to a lesser extent, triglycerides (TG).
  • Through seven decades the inverse association between HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease (ASCVD) has been observed in case-control and prospective cohor…
  • AIMS: The 2023 American Heart Association Predicting Risk of Cardiovascular Disease (CVD) EVENTs (PREVENT) risk equations allow for 10- and 30-year atherosclerotic CVD (ASCVD) quantitative risk asses…

Risks & harms

1 study reports safety-relevant findings. Design mix: Randomized controlled trial. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included men with preexisting or high cardiovascular risk.

What remains uncertain

  • HDL as a treatment target remains disputed after neutral outcome trials.
  • HDL as a treatment target remains disputed after neutral outcome trials.
  • Observational association is not evidence of treatment efficacy.
  • Surrogate improvement does not prove a hard clinical outcome.

Clinical takeaway

Do not add niacin or CETP inhibitors solely to raise HDL when LDL is already treated. Focus on LDL/apoB reduction and global risk; raising HDL pharmacologically has not consistently reduced events in outcome trials.

Negative link

LDL-C?

A negative association

high[31447131 · 22607822 · 18997196 · 34773460 · 38700053 · 42526419]

Positive link

Major adverse cardiovascular events?

A positive association

moderate[34637926 · 18997196 · 41403046 · 42291041 · 22910756 · 42526419]

Negative link

Mortality?

A negative association

moderate[22607822 · 42291041]

Unclear

Apolipoprotein B?

Unclear findings

limited[34773460 · 38700053]

Unclear

Blood pressure?

Unclear findings

limited[41101894]

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

9 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Evidence beyond long follow-up windows and in certain subgroups remains less complete.

11 analyzed studies

Strongest evidence

Biochimica et biophysica acta. Molecular and cell biology of lipids2022

Landmark studyPMID 34637926

HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics.

Through seven decades the inverse association between HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease (ASCVD) has been observed in case-control and prospective cohort studies. This robust inverse association fuelled the enthusiasm towards development of HDL cholesterol increasing drugs, exemplified by the cholesteryl ester transfer protein (CETP) inhibitor trials and the extended-release niacin HPS2-THRIVE trial.

Review
Evidence
Relevance
Clinical therapeutics2019

Landmark studyPMID 31447131

Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial of patients at high risk of vascular disease found that adding extended-release niacin-laropiprant to intensive statin-based LDL-lowering therapy had no benefit on cardiov

RCT
Evidence
Relevance

Supporting literature

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.

+6 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Cardiometabolic Risk.

Is ApoB more useful than LDL-C for cardiovascular risk prediction?

Prospective cohorts and meta-analyses suggest ApoB may capture atherogenic particle burden better than LDL-C alone, particularly when triglycerides are elevated or LDL particles are discordant with LDL-C.

14 linked studies

Should adults take statins for primary cardiovascular prevention?

Meta-analyses of primary prevention trials show reduced major adverse cardiovascular events with statins in appropriately selected moderate-to-high-risk adults. Shared decision-making should weigh absolute risk reduction against side effects and patient preference.

12 linked studies

Does elevated lipoprotein(a) independently increase cardiovascular risk?

Mendelian randomization and epidemiologic data support Lp(a) as a causal cardiovascular risk factor. Specific Lp(a)-lowering therapies are emerging but routine treatment beyond standard risk factor control awaits outcome trial confirmation.

11 linked studies

Does hormone therapy improve metabolic syndrome markers?

Menopausal hormone therapy may favorably affect some metabolic markers in selected women but is not a primary treatment for metabolic syndrome. Lifestyle and cardiometabolic risk management remain foundational.

14 linked studies

Go deeper on Cardiometabolic Risk

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Cardiometabolic RiskView pricing